Agenus Inc (AGEN) Incorporates NCI In Evaluation Of Prophage-Keytruda Combo
Having agreed on a collaborative deal, Agenus Inc (NASDAQ:AGEN) and National Cancer Institute (NCI) will work together in evaluating Agenus’ personalized autologous vaccine candidate, Prophage (HSPPC-96). MRK PD-1 therapy, Keytruda from Merck & Co., Inc.(NYSE:MRK) will also be incorporated. Merck’s inclusion comes on the back of its incredible performance in the past year having recorded […]